Haemonetics (HAE) Director Martin D. Madaus Receives RSU Award

What Happened

• Martin D. Madaus, a director of Haemonetics Corporation (HAE), received an award of 2,538 restricted stock units (RSUs) on July 24, 2026. The filing shows an acquisition-type transaction (award); no per-share price or immediate share delivery is reported (N/A).
• These RSUs are contingent rights to common stock and do not represent current share ownership until they vest.

Key Details

• Transaction date: 2026-07-24; Form 4 filed: 2026-07-28.
• Transaction type/code: Award/Grant (A).
• Shares/units granted: 2,538 RSUs; price: N/A (no cash paid).
• Vesting: 100% vests on the first anniversary of the grant (per footnote).
• Each RSU entitles the holder to one share upon vesting.
• Shares owned after the transaction: not specified in this filing.
• Footnotes: RSUs issued under the Haemonetics 2019 Long‑Term Incentive Compensation Plan; conversion to shares occurs when vested.

Context

• This is a standard equity compensation award (not an open‑market purchase or sale), so it does not reflect an immediate buy or sell signal. RSU grants are common for aligning director incentives with shareholder value; the economic interest exists only after vesting and any required issuance.